Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6709661B1 · kind B1 · utility
4Cited by
11References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 1997 |
| Grant date | Mar 23, 2004 |
| Priority date | — |
| Expiry date | Feb 12, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/806
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.